Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NicOx files anti-inflammatory naproxcinod for osteoarthritis in EU

This article was originally published in Scrip

Executive Summary

NicOx has filed its lead compound, the anti-inflammatory naproxcinod, for the relief of the signs and symptoms of osteoarthritis in Europe. The drug has already been filed in the US, where it has a PDUFA date of July 24th, 2010.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC006186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel